Anticipating Heron Therapeutics' Breakout on Phase 3 Results
AI Prediction of Heron Therapeutics, Inc. (HRTX)
Heron Therapeutics, with its robust pipeline and strong R&D focus, is poised for potential growth driven by upcoming catalysts, including a major Phase 3 clinical trial result. The company's strategic focus on pharmaceutical preparations positions it well in the biotech sector for a potential breakout.
HRTX Report Information
Prediction Date2025-07-03
Close @ Prediction$2.20
Mkt Cap171m
IPO DateN/a
AI-derived Information
Recent News for HRTX
- Feb 26, 4:33 pm — Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
- Feb 26, 4:09 pm — Heron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
- Feb 26, 3:48 pm — Heron Therapeutics Q4 Earnings Call Highlights (MarketBeat)
- Feb 26, 12:30 pm — Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
- Feb 26, 8:19 am — Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
- Feb 26, 8:00 am — Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
- Feb 17, 8:30 am — Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 (GlobeNewswire)
- Jan 10, 9:35 am — Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M (TipRanks)
- Jan 9, 9:29 am — Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth (GlobeNewswire)
- Dec 4, 8:15 am — Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) (GlobeNewswire)
- Nov 4, 4:06 pm — Heron Therapeutics Inc (HRTX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
- Nov 4, 9:30 am — Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
NDAPR (News-Driven AI Prediction Revision) events for HRTX
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.